Thailand Anti-hypertensive Drugs Market Size & Outlook

The anti-hypertensive drugs market in Thailand is expected to reach a projected revenue of US$ 141.2 million by 2030. A compound annual growth rate of 5.1% is expected of Thailand anti-hypertensive drugs market from 2024 to 2030.
Revenue, 2023 (US$M)
$99.8
Forecast, 2030 (US$M)
$141.2
CAGR, 2024 - 2030
5.1%
Report Coverage
Thailand

Thailand anti-hypertensive drugs market, 2018-2030 (US$M)

Thailand

Thailand anti-hypertensive drugs market highlights

  • The Thailand anti-hypertensive drugs market generated a revenue of USD 99.8 million in 2023 and is expected to reach USD 141.2 million by 2030.
  • The Thailand market is expected to grow at a CAGR of 5.1% from 2024 to 2030.
  • In terms of segment, primary hypertension was the largest revenue generating type in 2023.
  • Secondary Hypertension is the most lucrative type segment registering the fastest growth during the forecast period.


Anti-hypertensive drugs market data book summary

Market revenue in 2023USD 99.8 million
Market revenue in 2030USD 141.2 million
Growth rate5.1% (CAGR from 2023 to 2030)
Largest segmentPrimary hypertension
Fastest growing segmentSecondary Hypertension
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPrimary Hypertension, Secondary Hypertension
Key market players worldwideSanofi SA, Boehringer Ingelheim Pharma, Novartis AG ADR, Johnson & Johnson, Daiichi Sankyo Co Ltd, Merck & Co Inc, AstraZeneca PLC, Pfizer Inc, Lupin, Sun Pharmaceutical Industries


Other key industry trends

  • In terms of revenue, Thailand accounted for 0.4% of the global anti-hypertensive drugs market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, China anti-hypertensive drugs market is projected to lead the regional market in terms of revenue in 2030.
  • India is the fastest growing regional market in Asia Pacific and is projected to reach USD 2,036.8 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Anti-hypertensive Drugs Market Scope

Anti-hypertensive drugs market segmentation & scope
Primary Hypertension
Secondary Hypertension
Diuretics
ACE Inhibitors
Calcium Channel Blockers
Beta-adrenergic Blockers
Vasodilators
Others Drug Classes
Oral
Injectables
Other Route of Administration
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy

Anti-hypertensive Drugs Market Companies

Name Profile # Employees HQ Website

Thailand anti-hypertensive drugs market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-hypertensive drugs market will help companies and investors design strategic landscapes.


Primary hypertension was the largest segment with a revenue share of 71.04% in 2023. Horizon Databook has segmented the Thailand anti-hypertensive drugs market based on primary hypertension, secondary hypertension covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to Thailand anti-hypertensive drugs market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Thailand anti-hypertensive drugs market databook

  • Our clientele includes a mix of anti-hypertensive drugs market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Thailand anti-hypertensive drugs market, including forecasts for subscribers. This country databook contains high-level insights into Thailand anti-hypertensive drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Thailand anti hypertensive drugs market report size, by type, 2018-2030 (US$M)

Thailand Anti-hypertensive Drugs Market Share, 2023 & 2030 (US$M)

Thailand anti hypertensive drugs market report size, by type, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more